Result of Fundraising

Deltex Medical Group PLC
06 May 2003


6 May 2003


          Deltex Medical Group plc ('Deltex Medical' or the 'Company')

                          Fundraising Fully Subscribed


Chichester, United Kingdom - Deltex Medical (AIM: DEMG) today announces that,
further to the announcement made on 1 April 2003 stating that it had raised
approximately £815,000, the Company has received additional firm subscriptions
from various institutional and other investors in respect of 7,215,929 new
ordinary shares at 7p per share.  Of these new ordinary shares, 6,214,573 are to
be issued pursuant to a specific shareholder authority in relation to the
fundraising and 1,001,356 are to be issued pursuant to a general shareholder
authority.  The additional subscriptions, representing approximately £505,000,
bring the total amount of funds raised to approximately £1.32 million before
expenses.

The net proceeds from the fundraising will be used by the Company as additional
working capital to expand further the Group's penetration in the UK market, in
particular in hospital operating theatres, as well as to develop the Group's
business in overseas markets.

Application will be made for the 7,215,929 additional new ordinary shares to be
admitted to trading on AIM.  Admission is expected to become effective on 12 May
2003.

Nigel Keen, Chairman of Deltex Medical, said:

'We are delighted that the fundraising was fully subscribed.   With this
additional capital we will be able to consolidate our growing market share and
make further strides towards realising our goal to make haemodynamic
optimisation guided by the CardioQ a standard of care in operating theatres,
intensive care units and accident and emergency departments worldwide.'





Enquiries

Deltex Medical Group plc
Nigel Keen, Chairman
[e-mail]
01243 774 837

Andy Hill, Chief Executive
[e-mail]
01243 774 837

Ewan Phillips, Finance Director
[e-mail]
01243 774 837

Financial Dynamics
Stephanie Highett/Francetta Carr
[e-mail]
020 7831 3113



Notes for Editors

Deltex Medical primarily develops, assembles and markets a cardiac function
monitor and therapy guidance device, the CardioQ ('CardioQ'/'Monitor'). The
CardioQ incorporates the Company's proprietary software and a small diameter,
easy-to-use, minimally invasive, disposable oesophageal probe that is used for
transmitting and receiving an ultra-sound ('Doppler') signal. By using this
Doppler technology, the CardioQ provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.

There are already over 800 CardioQs currently in use in hospitals worldwide and
distribution arrangements are in place in over 30 countries. In addition, there
are currently more than 75 clinical publications on the use of the CardioQ which
have repeatedly:-

  * validated the results of the Monitor against known standards for measuring
cardiac output, demonstrating that the technology works

  * proved that the CardioQ works in a wide range of surgical procedures

  * demonstrated that the Company's technology provides significant health and
economic benefits by helping to reduce post-operative complications and length
of hospital stays by an average of 30 to 40 per cent for a wide range of
patients.

The Company is also currently developing a number of new products:-

  * the SupraQ - a monitor based on the CardioQ technology but using a
completely non-invasive probe; the prototype is being prepared for clinical
testing

  * the NeuroQ - a monitor designed to measure blood flow in the brain; the new
prototype is in preparation for clinical trials.


                      This information is provided by RNS
            The company news service from the London Stock Exchange                   FE